OGR for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General prescription drug affordability and access. Intellectual Property issues. PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022. Provisions related to the pharmaceutical industry; FY2023 Appropriations Process; monitoring COVID Supplemental Funding. Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation). Privacy issues; H.R.8152, American Data Privacy and Protection Act. 340B drug discount program policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Medicare/Medicaid MMM
Medicare Part D access and drug pricing negotiation; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376). Compulsory licensing policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.